Krankenhaus Martha-Maria Halle-Dölau - Klinik für Innere Medizin II
Herr Prof. CA Dr. med. W. Schütte
Übersicht Pneumologische Studien

31.03.2022

MARTHA MARIA
Unternehmen Menschlichkeit

NSCLC					
Studienkürzel	**Studientitel**	**Stadien/ Regimen**		**Histo**	**Medikamente**
AstraZeneca Prot.D9103C00001 Pacific-4	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresectable Stage I/II, lymph node negative NSCLC	I,II		NSCLC Platte und nicht-Platte	Durvalumab Vs. Placebo (nach RTX)
AbbVie Prot. M14-239 – Luminosity	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer	IIIb/IV	2nd/3rd L	NSCLC - nicht-Platte EGFR wt c-Met+	Telisotuzumab Vedotin i.v. mono bis PD
AstraZeneca Prot. D516AC00001 NeoADAURA	A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	II – III B (N2)	Neoadj.	NSCLC nicht-Platte EGFR pos.	Neoadj. 3 Z CTx Arm 1: A/C/ + Placebo vs. Arm2: A/C/Osi vs. Arm 3: Osi mono danach OP im Anschluss adj. Osimertinib b.B.
GlaxoSmithKline Prot. 213400 – ZEAL-1	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants whose Disease has Remained Stable or Responded to First-line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV NSCLC	IIIb/IV	1st line	NSCLC Platte und nicht-Platte Erhaltung nach 4-6 Z Ind. CTx	Nach 4 Zyklen Ind.CTx mit Platin-doublet + Pembro Erhaltung mit Pembro + Niraparib p.o. Vs. Pembro + Placebo p.o.
Mirati Prot. 849-012 KRYSTAL-12	A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	IV	2nd/3rdL	NSCLC Platte und nicht-Platte KRAS G12C pos.	Adagrasib p.o. vs. Docetaxel
Mirati Prot. MRT516-005 Sapphire	A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (Sapphire)	IIIB/IV	2nd line	NSCLC nicht-Platte	Nivolumab + Sitravatinib p.o. versus Docetaxel
SCLC					
Studienkürzel	**Studientitel**	**Stadien/ Regimen**		**Histo**	**Medikamente**
Roche Prot. GO43104 IMforte	A phase III, randomized, open-Label, multicenter study of Lurbinectedin in combination with Atezolizumab compared with Atezolizumab as maintenance therapy in participants with extensive-stage Small-cell lung cancer (ES-SCLC) following first-line induction therapy with Carboplatin, Etoposide and Atezolizumab	ES-SCLC	1st line	SCLC	Nach 4 Zyklen Ind.CTx mit Carbo/Eto/Atezo Erhaltung mit Atezo + Lurbinectidin i.v. Vs. Atezo
AIO-Studien gGmbH Prot.AIO-TRK-0119 SPACE	Single Arm Phase II-Study in patients with extensive stage SCLC with poor performance status receiving Atezolizumab-Carboplatin-Etoposide	ES-SCLC	1st line **Nur ECOG 2!**	SCLC	Atezo / Carbo / Eto

Krankenhaus Martha-Maria Halle-Dölau - Klinik für Innere Medizin II
Herr Prof. CA Dr. med. W. Schütte
Übersicht Pneumologische Studien

31.03.2022

MARTHA MARIA
Unternehmen Menschlichkeit

NIS NSCLC					
Signature Diagnostics GmbH Prot. ZRLK	Zeitreihenuntersuchung von **im Blut-Plasma nachweisbarer Biomarker** inklusive genetischer Marker im Lungenkarzinom	III/IV	1st-line	NSCLC Platte und nicht-Platte	Biomarkertestung im Blutplasma
AIO-Studien gGmbH Prot.AIO-TRK-0315 CRISP	Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (Einschluss bis max. 4 Wo. Nach Beginn Chemo)	IIIB/IV od. adj.	1st line	NSCLC Platte und nicht-Platte / SCLC	molecular testing, Fragebogen
Böhringer Ingelheim Prot. Vargado	NIS zu Vargatef in Kombination mit Docetaxel in der Zweitlinientherapie beim fortgeschrittenen, metastasierten oder lokal rezidivierten Adenokarzinom der Lunge. (Als 1st line auch Kombi Immun+Chemo erlaubt)	IIIb/IV	2nd line	NSCLC nicht-Platte	Vargatef + Docetaxel
NIS Lungenfibrose					
Böhringer Ingelheim Prot. INREAL	Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing ILD with a progressive phenotype.				Ofev (Nintedanib)